|
August 3-5, 2009
(August 3-4 main conference, August 5 post-conference workshop*)
可以产生令人振奋、临床前期与临床试验结果之实践策略
新世代抗体医药的发现•开发竞赛仍积极持续中。藉由将抗体与药剂与细胞毒素结合，来提高抗体功效与潜力的新方法正在进行研发中。此外，在增强治疗效果的各种结合中，测试何种组合才能具有最佳功效之实验，亦正在同时进行。在这个会议，从事抗体结合研究工作之领先企业，将分享最新的临床前期及临床试验结果，并公开多项抗体结合工程的最新数据。 另外，会议将介绍无论是对肿瘤病患，或是非肿瘤病患， 具有2种以上标靶之抗体医药的开发实践战略。同时，亦将介绍关于抗体投递战略，以及药理生物标记的用法。
Why You Should Attend:
- Hear preclinical and clinical data from multiple antibody development projects
- Meet all of the leading companies who are innovating in the field of antibody conjugation
- Discover emerging trends in antibody technology development and biomarkers for antibody drugs
Confirmed Speakers and Sessions
(As of March 10, 2009)
Antibody-Drug Conjugates and Other Conjugation Strategies
- Paul Polakis, Ph.D., Director, Cancer Targets, Genentech. Inc.
- Vincent de Groot, Ph.D., Chief Executive Officer, Syntarga B.V., The Netherlands
- Aya Jakobovits, Ph.D., Executive Vice President and Head, Research and Development Agensys, Inc.
- William C. Olson, Ph.D., Senior Vice President, R&D, Progenics Pharmaceuticals, Inc.
- S.V. Govindan, Ph.D., Senior Director, Conjugation, Immunomedics, Inc.
- Michele Sanicola-Nadel, Ph.D., Associate Director, Tumor Cell Growth and Adhesion, Discovery Oncology, Biogen Idec
- Erik R Vandendries, M.D., Ph.D., Associate Director, Clinical Research and Development, Hematology Medical Research, Wyeth Research
- Nils Lonberg, Ph.D., Senior Vice President, Scientific Director, Medarex
- John M. Lambert, Ph.D., Executive Vice President and Chief Scientific Officer, ImmunoGen, Inc.
- Jonathan Drachman, M.D., Vice President Translational Medicine, Seattle Genetics, Inc.
- Barbara Klencke, M.D., Group Medical Director, Genentech, Inc.
- Ronit Simantov, M.D., Chief Medical Officer, CuraGen Corporation
Approaches to Improve Antibody Efficacy and Potency
- Sanjay D. Khare, Ph.D., President, R&D, ImmunGene, Inc.
- John R. Desjarlais, Ph.D., Vice President, Research, Xencor, Inc.
- Frank Calzone, Ph.D., Executive Scientific Director, Oncology Research, Amgen, Inc.
- Alison Humbles, Ph.D., Senior Scientist, Department of Respiratory, Inflammation and Autoimmunity, Medimmune, LLC
- Tobias Raum, Ph.D., Senior Director Lead Discovery, Human Antibody Technologies, Micromet AG, Germany
Bispecific and Multispecific Antibody Drugs
- Charlotte McDonagh, Ph.D., Associate Director, Merrimack Pharmaceuticals, Inc.
- Tariq Ghayur, Ph.D., Senior Principal Scientist & Research Fellow, Abbott Bioresearch Center
- Robert Mabry, Ph.D., Senior Scientist, Department of Protein Engineering, ZymoGenetics, Inc.
Combinations of Antibody Therapies
- Mark Pegram, M.D., Professor, University of Miami
- David M. Goldenberg, ScD, MD; Founder and Chairman, Immunomedics, Inc.
Pharmacodynamic Biomarkers in Antibody Development
- Antonio Gualberto, M.D., Ph.D., Director and Global Clinical Leader, Oncology, Pfizer Global R&D
- Barbara White, M.D., Vice President of Clinical Development, Medimmune
Post-Conference Workshop: Understanding and Exploiting The Role of Cancer Stem Cells in Drug Development
- Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
- Jeff Jackson, Ph.D., Director, Cancer Stem Cell DPU, Oncology R&D, GlaxoSmithKline
- Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc. West
- Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.
- Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology
- Lyuba Varticovski, Staff Clinician, National Cancer Institute
Scientific Advisory Board
Ulrik Nielsen, Ph.D., Senior Vice President, Research, Merrimack Pharmaceuticals
Zhenping Zhu, M.D., Ph.D., Vice President, Antibody Technology, ImClone Systems
William Dall'Acqua, Ph.D., Director, R&D, MedImmune, Inc.
Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex, Inc.
Taruna Arora, Ph.D., Principal Scientist, Antibody Research, Amgen, Inc.
|
